Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. Lenalidomide is eliminated renally. No interaction is expected with emtricitabine as lenalidomide does not inhibit renal transporters. However, lenalidomide has been associated with serious nephrotoxicity including proximal and distal tubular damage, glomerular effects and Fanconi syndrome. Use of tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic medicinal product. If coadministration is unavoidable, renal function should be monitored closely.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking